| Cardiac Imaging and Diagnostics | Lifetime | 35 | US 22 | 99.92 |
| Acute Myocardial Infarction Research | Lifetime | 24 | US 16 | 99.90 |
| Cardiac, Anesthesia and Surgical Outcomes | Lifetime | 192 | US 102 | 99.49 |
| Cardiac electrophysiology and arrhythmias | Lifetime | 179 | US 98 | 99.44 |
| Cardiovascular Effects of Exercise | Lifetime | 79 | US 39 | 99.40 |
| Cardiac Health and Mental Health | Lifetime | 87 | US 50 | 99.08 |
| Cardiovascular Function and Risk Factors | Lifetime | 305 | US 181 | 99.41 |
| Heart Failure Treatment and Management | Lifetime | 145 | US 77 | 99.42 |
| Coronary Interventions and Diagnostics | Lifetime | 249 | US 118 | 99.20 |
| Lipoproteins and Cardiovascular Health | Lifetime | 417 | US 199 | 98.24 |
| Hemodynamic Monitoring and Therapy | Lifetime | 374 | US 144 | 97.84 |
| Cardiac Arrest and Resuscitation | Lifetime | 811 | US 436 | 98.02 |
| Cardiac Structural Anomalies and Repair | Lifetime | 683 | US 405 | 98.12 |
| Atrial Fibrillation Management and Outcomes | Lifetime | 893 | US 343 | 97.98 |
| Cardiac Fibrosis and Remodeling | Lifetime | 239 | US 95 | 96.52 |
| GDF15 and Related Biomarkers | Lifetime | 98 | US 40 | 93.58 |
| Takotsubo Cardiomyopathy and Associated Phenomena | Lifetime | 117 | US 43 | 93.89 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | Lifetime | 673 | US 273 | 93.61 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 760 | US 324 | 89.03 |
| Potassium and Related Disorders | Lifetime | 614 | US 292 | 89.71 |
| Heart rate and cardiovascular health | Lifetime | 198 | US 65 | 88.04 |
| Acute Myocardial Infarction Research | 2021-2025 | 60 | US 25 | 98.85 |
| Cardiac Imaging and Diagnostics | 2021-2025 | 249 | US 80 | 98.12 |
| Cardiac, Anesthesia and Surgical Outcomes | 2021-2025 | 828 | US 291 | 93.69 |
| Coronary Interventions and Diagnostics | 2021-2025 | 709 | US 149 | 92.54 |
| Cardiovascular Effects of Exercise | 2021-2025 | 606 | US 166 | 86.92 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 893 | US 249 | 86.22 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 939 | US 209 | 84.06 |
| Sphingolipid Metabolism and Signaling | 2021-2025 | 874 | US 229 | 53.94 |
| Biomarkers in Disease Mechanisms | 2021-2025 | 661 | US 48 | 46.81 |
| Medical Coding and Health Information | 2021-2025 | 403 | US 73 | 21.47 |
